Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02210247 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers
A Phase 1 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02210247 is a Phase 1 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT02210247, a Phase 1 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of redosing EXPAREL via local subcutaneous infiltration in healthy volunteers.
Interventions
- DRUG EXPAREL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02210247
The ClinicalTrials.gov registry entry for NCT02210247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EXPAREL is the first listed.
NCT02210247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02210247 about?
NCT02210247 is a clinical study titled "Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers". The purpose of this study is to evaluate the safety and pharmacokinetics of redosing EXPAREL via local subcutaneous infiltration in healthy volunteers.
What is the current status of trial NCT02210247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2014-08. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02210247?
The interventions under investigation include: EXPAREL (DRUG).
Who is sponsoring clinical trial NCT02210247?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.